Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma

Nicola Silvestris, Vito Longo, Francesco Cellini, Michele Reni, Alessandro Bittoni, Ivana Cataldo, Stefano Partelli, Massimo Falconi, Aldo Scarpa, Oronzo Brunetti, Vito Lorusso, Daniele Santini, Alessio Morganti, Vincenzo Valentini, Stefano Cascinu

Research output: Contribution to journalArticle

Abstract

Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.

Original languageEnglish
Pages (from-to)309-324
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume98
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Combined Modality Therapy
Neoadjuvant Therapy
Adenocarcinoma
Guidelines
Therapeutics
Drug Therapy
Biomarkers
Clinical Trials
Radiation

Keywords

  • Borderline
  • Chemotherapy
  • Locally advanced
  • Neoadjuvant
  • Pancreatic ductal adenocarcinoma
  • Radiotherapy
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. / Silvestris, Nicola; Longo, Vito; Cellini, Francesco; Reni, Michele; Bittoni, Alessandro; Cataldo, Ivana; Partelli, Stefano; Falconi, Massimo; Scarpa, Aldo; Brunetti, Oronzo; Lorusso, Vito; Santini, Daniele; Morganti, Alessio; Valentini, Vincenzo; Cascinu, Stefano.

In: Critical Reviews in Oncology/Hematology, Vol. 98, 01.02.2016, p. 309-324.

Research output: Contribution to journalArticle

Silvestris, N, Longo, V, Cellini, F, Reni, M, Bittoni, A, Cataldo, I, Partelli, S, Falconi, M, Scarpa, A, Brunetti, O, Lorusso, V, Santini, D, Morganti, A, Valentini, V & Cascinu, S 2016, 'Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma', Critical Reviews in Oncology/Hematology, vol. 98, pp. 309-324. https://doi.org/10.1016/j.critrevonc.2015.11.016
Silvestris, Nicola ; Longo, Vito ; Cellini, Francesco ; Reni, Michele ; Bittoni, Alessandro ; Cataldo, Ivana ; Partelli, Stefano ; Falconi, Massimo ; Scarpa, Aldo ; Brunetti, Oronzo ; Lorusso, Vito ; Santini, Daniele ; Morganti, Alessio ; Valentini, Vincenzo ; Cascinu, Stefano. / Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. In: Critical Reviews in Oncology/Hematology. 2016 ; Vol. 98. pp. 309-324.
@article{08e353fbf6c940268914c442215e361e,
title = "Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma",
abstract = "Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.",
keywords = "Borderline, Chemotherapy, Locally advanced, Neoadjuvant, Pancreatic ductal adenocarcinoma, Radiotherapy, Target therapy",
author = "Nicola Silvestris and Vito Longo and Francesco Cellini and Michele Reni and Alessandro Bittoni and Ivana Cataldo and Stefano Partelli and Massimo Falconi and Aldo Scarpa and Oronzo Brunetti and Vito Lorusso and Daniele Santini and Alessio Morganti and Vincenzo Valentini and Stefano Cascinu",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.critrevonc.2015.11.016",
language = "English",
volume = "98",
pages = "309--324",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma

AU - Silvestris, Nicola

AU - Longo, Vito

AU - Cellini, Francesco

AU - Reni, Michele

AU - Bittoni, Alessandro

AU - Cataldo, Ivana

AU - Partelli, Stefano

AU - Falconi, Massimo

AU - Scarpa, Aldo

AU - Brunetti, Oronzo

AU - Lorusso, Vito

AU - Santini, Daniele

AU - Morganti, Alessio

AU - Valentini, Vincenzo

AU - Cascinu, Stefano

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.

AB - Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.

KW - Borderline

KW - Chemotherapy

KW - Locally advanced

KW - Neoadjuvant

KW - Pancreatic ductal adenocarcinoma

KW - Radiotherapy

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=84957638630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957638630&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.11.016

DO - 10.1016/j.critrevonc.2015.11.016

M3 - Article

AN - SCOPUS:84957638630

VL - 98

SP - 309

EP - 324

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -